| Identification | Back Directory | [Name]
JNJ-632 | [CAS]
1572510-42-9 | [Synonyms]
JNJ-632
CS-2776
JNJ-632; JNJ 632; JNJ632
N-(4-fluoro-3-methylphenyl)-3-[[(3S)-oxolan-3-yl]sulfamoyl]benzamide
N-(4-fluoro-3-methyl-phenyl)-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzamide
N-(4-Fluoro-3-methylphenyl)-3-[[[(3S)-tetrahydro-3-furanyl]amino]sulfonyl]benzamide
Benzamide, N-(4-fluoro-3-methylphenyl)-3-[[[(3S)-tetrahydro-3-furanyl]amino]sulfonyl]- | [Molecular Formula]
C18H19FN2O4S | [MDL Number]
MFCD31692402 | [MOL File]
1572510-42-9.mol | [Molecular Weight]
378.42 |
| Chemical Properties | Back Directory | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Ethanol:76.0(Max Conc. mg/mL);200.84(Max Conc. mM) | [form ]
A crystalline solid | [pka]
10.37±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM). | [in vivo]
The single dose PK profile of JNJ-632 is evaluated in C57BL/6 mice following intravenous (iv) and oral (po) administration. JNJ-632 has a moderate plasma clearance of 34 mL/min/kg and a moderate volume of distribution of 1.3 L/kg. The oral bioavailability is 40% following oral administration of 10 mg/kg and 66% following oral administration of 50 mg/kg. JNJ-632 has moderate terminal elimination half-life with t1/2s of 0.42±0.06 h, 1.1±0.67 h, 2.4±2.3 h, and 5.3±0.1 h for 2.5 mg/kg (iv), 10 mg/kg (po), 50 mg/kg (po), and 50 mg/kg (sc).To circumvent the first pass metabolism, JNJ-632 is also dosed subcutaneously at 50 mg/kg in C57BL/6 mice and this results in a concentration in plasma after 24 h of dosing of 102 ng/mL and concentration in liver after 24 h of dosing of 1297 ng/g[1]. | [storage]
Store at -20°C | [References]
[1] Vandyck K, et al. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260. DOI:10.1021/acs.jmedchem.8b00654 |
|
|